Pairidex secured seed financing of $4.89 million to accelerate commercialization of FusionMRD, an RNA-based droplet digital PCR blood test for monitoring minimal residual disease in gene fusion-driven blood cancers. The company said its lab-developed test is already commercially available from its CLIA-certified and CAP-accredited laboratory, with initial focus on acute myeloid leukemia. FusionMRD is designed to detect fusion-driven AML in roughly 50% of patients and to support real-time treatment decision-making through more sensitive and less invasive detection. Pairidex said the round will also fund clinical studies, commercial expansion, and ongoing development of its personalized molecular diagnostics platform. The move reinforces a broader shift toward MRD measurement tools that integrate molecular sensitivity with practical clinical logistics outside traditional tissue biopsy constraints.